Gilead’s court clash creates ripple effect in combination drug pricing

Pharmaceutical companies with multiple PBS-listed medicines may face significant unintended pricing consequences where those treatments share a common active ingredient. A generic entrant targeting a single medicine will now trigger mandatory price reductions across a wider portfolio of combination therapies, creating material commercial implications for innovative medicines companies.

The Federal Court of Australia’s decision in Gilead Sciences Pty Ltd v Minister for Health and Ageing [2026] marks a significant development in the interpretation of the pharmaceutical pricing regime. The judgment adopts a broad interpretation of the statutory concepts of “combination item” and “listed component drug” under the National Health Act 1953, expanding the circumstances in which generic competition can produce downstream pricing impacts.

The case examined whether statutory price reductions arising from the listing of a generics on the Pharmaceutical Benefits Scheme (PBS) could extend beyond the directly competing product and apply to other combination medicines marketed by the same originator company.

The proceedings were commenced by Gilead, which sought an injunction against the Minister for Health and Ageing in an attempt to prevent the application of those price reductions to its broader portfolio of PBS-listed treatments.

Gilead has four products listed on the PBS: Descovy, Odefsey, Genvoya and Biktarvy. Descovy is the only product listed for the drug “emtricitabine with tenofovir alafenamide”, available in two tablet forms for oral administration.

The remaining products, Odefsey, Genvoya and Biktarvy, each contained the same combination of emtricitabine and tenofovir alafenamide, but also included additional active pharmaceutical ingredients. Each product was listed on the Combination Drug List (CDL), or was treated by the Minister for Health as falling within the scope of that list.

The dispute arose in January 2026 when Alphapharm registered a generic version of Descovy on the Australian Register of Therapeutic Goods (ARTG). The parties accepted that, following PBS listing of the generic product, statutory price reductions would apply to both the generic medicine and Descovy itself.

The central issue was whether those reductions would also extend to Odefsey, Genvoya and Biktarvy.

Gilead argued that the presence of additional active pharmaceutical ingredients meant those medicines could not be characterised as combination drugs containing the relevant listed component drug for the purposes of the legislation. The Minister for Health adopted a broader interpretation, maintaining that the shared component drug was sufficient to bring the products within the statutory pricing framework.

In the alternative, Gilead argued that if the Minister’s interpretation was accepted, regulation 65A of the National Health (Pharmaceutical Benefits) Regulations 2017 which establishes the formula for calculating price reductions was invalid because it was arbitrary and incapable of workable application.

The Federal Court rejected Gilead’s argument of the legislation and upheld the interpretation advanced by the Minister. The Court confirmed that statutory price reductions triggered by generic listing can extend to other combination products containing the same listed component drug, even where those products incorporate additional active ingredients.

Accordingly, the listing of generic Descovy was capable of triggering price reductions not only for Descovy itself, but also for Gilead’s related combination therapies Odefsey, Genvoya and Biktarvy.

The decision represents a significant shift in the commercial risk landscape for pharmaceutical companies with interconnected PBS treatments. Rather than operating as isolated pricing events, generic entries will now have broader portfolio-wide consequences, forcing manufacturers to reassess the regulatory exposure associated with combination therapies that share common active ingredients.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.